These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22606272)

  • 41. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    Button B; Croessmann S; Chu D; Rosen DM; Zabransky DJ; Dalton WB; Cravero K; Kyker-Snowman K; Waters I; Karthikeyan S; Christenson ES; Donaldson J; Hunter T; Dennison L; Ramin C; May B; Roden R; Petry D; Armstrong DK; Visvanathan K; Park BH
    Breast Cancer Res Treat; 2019 Apr; 174(2):401-412. PubMed ID: 30560461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
    Meijer D; Sieuwerts AM; Look MP; van Agthoven T; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2008 Mar; 15(1):101-11. PubMed ID: 18310279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
    Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
    Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
    J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Mitobe Y; Ikeda K; Suzuki T; Takagi K; Kawabata H; Horie-Inoue K; Inoue S
    Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31501276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
    Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
    Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.
    Atmaca A; Al-Batran SE; Wirtz RM; Werner D; Zirlik S; Wiest G; Eschbach C; Claas S; Hartmann A; Ficker JH; Jäger E; Brueckl WM
    Int J Cancer; 2014 May; 134(10):2314-21. PubMed ID: 24174373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
    Wolmark N; Mamounas EP; Baehner FL; Butler SM; Tang G; Jamshidian F; Sing AP; Shak S; Paik S
    J Clin Oncol; 2016 Jul; 34(20):2350-8. PubMed ID: 27217450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and
    Butler EN; Bensen JT; Chen M; Conway K; Richardson DB; Sun X; Geradts J; Olshan AF; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):67-74. PubMed ID: 29133365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.